Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Rosetta Genomics Appoints Kevin Watson

Published: Thursday, February 20, 2014
Last Updated: Wednesday, February 19, 2014
Bookmark and Share
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.

Rosetta Genomics Ltd. has announced the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care.

Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization.

"We are delighted to welcome Kevin to the Rosetta team to drive our reimbursement and managed care strategy and initiatives. Reimbursement is critical for commercial success and, as 2014 is a year of commercial execution for Rosetta, this is a timely and important hire for us," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "Kevin's experience devising strategic marketing, growth, and operational plans directed to the payer, integrated health system, hospital and distributor channels will be an invaluable asset for Rosetta as we execute our commercial plans for our current suite of cancer testing services and plan for the launch of future microRNA-based diagnostics."

Mr. Watson joins Rosetta Genomics from competing molecular diagnostics company, bioTheranostics, where for two years he was the Director of Reimbursement. Prior to this, Mr. Watson was the President of GlobalPayer, a payer relations and reimbursement consulting and outsourcing company serving providers and manufacturers in the medical device and diagnostic industry.

Mr. Watson was the Regional Marketing/Payer Relations Director at Becton Dickinson Diagnostics - TriPath Imaging for 6 years, where he was responsible for the development, execution and management of reimbursement outcomes with large payer organizations, Medicare and Medicaid.

Previous to that, Mr. Watson held positions as Executive Director, Business Development at LabCorp., and Network Product Development Leader, Executive Director with Quest Diagnostics, Inc. Mr. Watson started his career in payer management at Aetna Health Plans, where he spent four years as Administrator, National Vendor Contracting.

"This is an exciting time to be joining Rosetta to develop and manage the Company's payer relations strategy," said Kevin Watson. "Rosetta's cancer testing services provide critical and objective diagnostic data that may help physicians to select optimal treatment options and improve patient outcomes. I am looking forward to working with the Rosetta team as we build and expand the Company's microRNA diagnostic product offerings to bring truly personalized medicine to patients."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics Launch Admera’s Sequencing-Based Oncology Tests
The tests will help to predict patient’ responses to drugs based on their personal genetic makeup.
Monday, January 12, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics Expands Management Team
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.
Tuesday, August 26, 2014
Rosetta Genomics Announces Agreement with Global Pharmaceutical Company
Leverages Rosetta's microRNA biomarker platform and expertise and global pharmaceutical Company's expertise in Alzheimer's biology and drug development to develop a diagnostic for the early detection of Alzheimer's disease.
Tuesday, August 05, 2014
Rosetta Genomics Announces NGS Research Collaboration with Weizmann Institute
Developing novel methods for next-generation sequencing of small RNAs.
Friday, August 01, 2014
Rosetta Genomics Receives Final New York State Approval
Proprietary microRNA diagnostic for identification of four major subtypes of kidney cancer now available in all 50 U.S. states.
Saturday, July 26, 2014
Rosetta Receives Notice of Allowance for U.S. Patent for Ovarian Cancer Treatment
microRNA therapeutic approach complements company's ovarian cancer predictive biomarker work.
Saturday, July 12, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics, Clait Health Services Enter mRNA Collaboration
Partnership with Clalit Health Services' Rabin Medical Center will develop a non-invasive, microRNA-based, assay for the diagnosis of CAD following kidney transplantation.
Tuesday, March 25, 2014
Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.
Thursday, February 27, 2014
Rosetta Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer
Expands the Company's patent portfolio in oncology therapeutics.
Monday, November 11, 2013
Rosetta Genomics Announces Sponsored Research Agreement with Ramot at TAU
Joint development of nano-carrier delivery system for miR mimetic technology to treat cancer to be partially funded by Israel's Office of the Chief Scientist.
Tuesday, November 05, 2013
Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks
Adds approximately 44 million potential covered lives for the Rosetta Cancer Origin Test.
Monday, September 09, 2013
Rosetta Announces Exercise and Closing of Underwriter's Over-Allotment Option
Company announces sale of an additional 825,000 ordinary shares.
Wednesday, September 12, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos